Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 61Neoplasms 52Neoplasm Metastasis 48Leukemia, Myeloid, Acute 47Colorectal Neoplasms 47Breast Neoplasms 44Prostatic Neoplasms 37Multiple Myeloma 33Ovarian Neoplasms 31Recurrence 27Melanoma 26Pancreatic Neoplasms 25Lymphoma, Non-Hodgkin 25Squamous Cell Carcinoma of Head and Neck 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Myelodysplastic Syndromes 22Triple Negative Breast Neoplasms 21Endometrial Neoplasms 21Lung Neoplasms 19Carcinoma, Renal Cell 19Stomach Neoplasms 18Small Cell Lung Carcinoma 18Sarcoma 18Advanced Solid Tumors 18Brain Neoplasms 17Glioblastoma 16Carcinoma, Hepatocellular 16Esophageal Neoplasms 13Solid Tumors 12Lymphoma, B-Cell 12

Interventions

capivasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Moderate Hepatic Impairment × 30 days × Clear all
NCT07343960 2026-05-20

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

AstraZeneca

Phase 1 Recruiting
20 enrolled

Moderate Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡